PV
In a phase II study in HU-resistant or -intolerant PV patients, INC424, a potent and selective inhibitor of JAK1 and JAK2, was well tolerated and achieved rapid and durable clinical responses including phlebotomy independence, resolution of splenomegaly, and improvements in white blood cell counts, platelet counts, and disease-related symptoms (Verstovsek S, et al.